Cantor Fitzgerald Forecasts MREO FY2025 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Mereo BioPharma Group in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($0.08) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

Mereo BioPharma Group (NASDAQ:MREO) last posted its earnings results on Wednesday, March 26th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.03).

A number of other brokerages also recently issued reports on MREO. Needham & Company LLC reaffirmed a “buy” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a report on Wednesday, March 26th. Jefferies Financial Group assumed coverage on shares of Mereo BioPharma Group in a report on Friday, December 6th. They issued a “buy” rating and a $7.00 target price for the company. Lifesci Capital began coverage on shares of Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price target on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Mereo BioPharma Group in a research report on Thursday, March 27th. They issued an “overweight” rating and a $7.00 price target for the company. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $7.71.

Mereo BioPharma Group Stock Performance

MREO opened at $2.17 on Monday. Mereo BioPharma Group has a one year low of $2.11 and a one year high of $5.02. The company has a market cap of $336.67 million, a P/E ratio of -36.17 and a beta of 1.03. The business’s 50-day simple moving average is $2.69 and its 200-day simple moving average is $3.45.

Institutional Trading of Mereo BioPharma Group

A number of large investors have recently bought and sold shares of MREO. Newbridge Financial Services Group Inc. purchased a new stake in shares of Mereo BioPharma Group in the fourth quarter valued at about $37,000. Jump Financial LLC acquired a new position in Mereo BioPharma Group in the 4th quarter valued at about $39,000. Sheets Smith Investment Management acquired a new position in Mereo BioPharma Group in the 4th quarter valued at about $59,000. Virtus ETF Advisers LLC purchased a new stake in Mereo BioPharma Group during the 4th quarter valued at approximately $67,000. Finally, Avanza Fonder AB acquired a new stake in Mereo BioPharma Group during the 4th quarter worth approximately $69,000. Institutional investors and hedge funds own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.